Literature DB >> 23290786

Ultrasound-guided lymph node sampling in the initial management of breast cancer.

C Balu-Maestro1, A Ianessi, C Chapellier, C Marcotte, S Stolear.   

Abstract

Ultrasound-guided fine needle sampling is proving very useful for avoiding surgical biopsy of the sentinel lymph node for N+breast cancer. Because of its high specificity, cytology is sufficient in most cases. Focal or diffuse cortical thickening or the absence of the echogenic hilum irrespective of the size and shape of the lymph node are ultrasound signs which should be taken into account. The status of the lymph nodes in axillary and extra-axillary sites has an impact on the later management of patients and reduces the length of time for secondary lymph node dissection and adjuvant therapy, as one third of sentinel ganglion procedures can be avoided. It should be possible to optimise identification of the sentinel lymph node by the intradermal injection of ultrasound contrast agent. The cost/effectiveness ratio is positive but unknown and should be assessed in the initial management of breast cancer.
Copyright © 2012 Éditions françaises de radiologie. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23290786     DOI: 10.1016/j.diii.2012.06.007

Source DB:  PubMed          Journal:  Diagn Interv Imaging        ISSN: 2211-5684            Impact factor:   4.026


  3 in total

1.  Re: Predictive value of fine needle aspiration biopsy of axillary lymph nodes in preoperative breast cancer staging.

Authors:  Can Atalay
Journal:  Ulus Cerrahi Derg       Date:  2015-09-01

2.  Medical imaging in personalised medicine: a white paper of the research committee of the European Society of Radiology (ESR).

Authors: 
Journal:  Insights Imaging       Date:  2015-03-13

3.  3T MRI-Radiomic Approach to Predict for Lymph Node Status in Breast Cancer Patients.

Authors:  Domiziana Santucci; Eliodoro Faiella; Ermanno Cordelli; Rosa Sicilia; Carlo de Felice; Bruno Beomonte Zobel; Giulio Iannello; Paolo Soda
Journal:  Cancers (Basel)       Date:  2021-05-06       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.